DE69133281D1 - Rezeptoren der wachstumsfaktoren aus fibroblasten - Google Patents

Rezeptoren der wachstumsfaktoren aus fibroblasten

Info

Publication number
DE69133281D1
DE69133281D1 DE69133281T DE69133281T DE69133281D1 DE 69133281 D1 DE69133281 D1 DE 69133281D1 DE 69133281 T DE69133281 T DE 69133281T DE 69133281 T DE69133281 T DE 69133281T DE 69133281 D1 DE69133281 D1 DE 69133281D1
Authority
DE
Germany
Prior art keywords
domain
growth factor
fibroblast growth
factor receptors
repeats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69133281T
Other languages
English (en)
Other versions
DE69133281T2 (de
Inventor
A Dionne
Gregg Crumley
C Jaye
Joseph Schlessinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTELION, VITRY SUR SEINE, FR
Original Assignee
Rhone Poulenc Rorer International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24193610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69133281(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer International Holdings Inc filed Critical Rhone Poulenc Rorer International Holdings Inc
Publication of DE69133281D1 publication Critical patent/DE69133281D1/de
Application granted granted Critical
Publication of DE69133281T2 publication Critical patent/DE69133281T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69133281T 1990-07-06 1991-07-03 Rezeptoren der wachstumsfaktoren aus fibroblasten Expired - Lifetime DE69133281T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54958790A 1990-07-06 1990-07-06
US549587 1990-07-06
PCT/US1991/004745 WO1992000999A1 (en) 1990-07-06 1991-07-03 Fibroblast growth factor receptors

Publications (2)

Publication Number Publication Date
DE69133281D1 true DE69133281D1 (de) 2003-07-24
DE69133281T2 DE69133281T2 (de) 2004-05-06

Family

ID=24193610

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133281T Expired - Lifetime DE69133281T2 (de) 1990-07-06 1991-07-03 Rezeptoren der wachstumsfaktoren aus fibroblasten

Country Status (10)

Country Link
US (1) US6344546B1 (de)
EP (2) EP0538404B1 (de)
JP (2) JP3615220B2 (de)
AT (1) ATE243253T1 (de)
AU (1) AU662107B2 (de)
CA (1) CA2086425C (de)
DE (1) DE69133281T2 (de)
DK (1) DK0538404T3 (de)
ES (1) ES2204886T3 (de)
WO (1) WO1992000999A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228609B1 (en) * 1992-07-09 2001-05-08 Systemix, Inc. Soluble Flk-2 sequence
AU709191B2 (en) * 1995-09-11 1999-08-26 Osteoarthritis Sciences, Inc. Protein tyrosine kinase inhibitors for treating osteoarthritis
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
JP2002533128A (ja) * 1998-12-31 2002-10-08 アドバンスド リサーチ アンド テクノロジー インスティテュート アデノ随伴ウイルス２による感染のためのコレセプターとしてのヒト線維芽細胞増殖因子レセプター１
US6657078B2 (en) * 2001-02-07 2003-12-02 Celanese International Corporation Low energy carbonylation process
AU2006272759B2 (en) 2005-07-22 2012-01-12 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
RU2509774C2 (ru) 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
SG10201402038WA (en) 2009-05-05 2014-07-30 Amgen Inc FGF21 Mutants And Uses Thereof
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
EP2443145A1 (de) * 2009-06-17 2012-04-25 Amgen, Inc Chimäre fgf19-polypeptide und ihreverwendung
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
WO2011068893A1 (en) * 2009-12-02 2011-06-09 Amgen Inc. BINDING PROTEINS THAT BIND TO HUMAN FGFR1C, HUMAN β-KLOTHO AND BOTH HUMAN FGFR1C AND HUMANβ-KLOTHO
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
RU2012153241A (ru) 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
EP2640406A1 (de) 2010-11-15 2013-09-25 Five Prime Therapeutics, Inc. Behandlung von krebs mit erhöhten dosen löslicher fgfr1-fusionsproteine
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2780033B1 (de) 2011-11-14 2019-05-08 Five Prime Therapeutics, Inc. Eine fgfr1 extrazelluläre domäne zur behandlung von krebs mit einer fgfr1 gen vervielfältigung
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
ES2133271T3 (es) * 1989-07-06 1999-09-16 Univ California Receptores para factores de crecimiento de fibroblastos.

Also Published As

Publication number Publication date
JPH05508550A (ja) 1993-12-02
EP0538404A1 (de) 1993-04-28
EP0538404A4 (en) 1993-05-26
ES2204886T3 (es) 2004-05-01
JP3615220B2 (ja) 2005-02-02
EP0538404B1 (de) 2003-06-18
WO1992000999A1 (en) 1992-01-23
AU662107B2 (en) 1995-08-24
CA2086425C (en) 2006-01-17
JP2004041176A (ja) 2004-02-12
JP3996084B2 (ja) 2007-10-24
ATE243253T1 (de) 2003-07-15
US6344546B1 (en) 2002-02-05
DK0538404T3 (da) 2003-10-13
AU8427391A (en) 1992-02-04
CA2086425A1 (en) 1992-01-07
EP1403285A1 (de) 2004-03-31
DE69133281T2 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
DE69133281D1 (de) Rezeptoren der wachstumsfaktoren aus fibroblasten
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
NO931955L (no) Reseptorer for leukemiinhiberende faktor
AR017510A1 (es) Polinucleotido aislado o recombinante, vector de expresion, celula huesped, metodo para preparar un polipeptido antigenico, metodo y equipo para ladeteccion de un polinucleotido, compuesto de union, metodo de empleo del compuesto de union, polipeptido antigenico aislado o substancialmente puro, ymet
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
IT1242149B (it) Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
ATE122397T1 (de) Fusionsproteine aus interleukin-2 und hirudin.
CA2067031A1 (en) Dna coding for human cell surface antigen
DK0618976T3 (da) Syntetisk DNA-sekvens med forbedret insekticid virkning i majs
DE69737978D1 (de) Als 2f1 bezeichnetes rezeptorprotein
CY1107173T1 (el) Μεθοδοι και κυτταρα για την εκφραση ανασυνδυασμενων πρωτεϊνικων προϊοντων
YU79491A (sh) Varijantni cd44-površinski proteini, dna-sekvence koje ih kodiraju i antitela protiv ovih proteina
NO940736L (no) DNA sekvenser som koder for gelonin polypeptid
FI971896A0 (fi) BMP-tyyppi II-reseptoria koodaava cDNA
IL126679A0 (en) Type c lectins
NO970113D0 (no) Kollagenbindende protein eller polypeptid
WO2001055103A3 (en) Chimeric neuropeptide y receptors
DE69333284D1 (de) Polypeptide mit serotoninerger (5ht5a) rezeptor-aktivität, für sie kodierende nukleinsäuren und ihre verwendung
DK199900825A (da) Klonede glucagon-lignende peptid-2-receptorer
EP1140968A4 (de) Dna-moleküle kodierende spleissvarianten des humanen melanocortin-1-rezeptorproteins
ATE454450T1 (de) Proteine, das auf hämatopoietischen stammzellen der lymphoid und nk linien zu finden ist, und verwendungen davon
ATE410513T1 (de) 'patched-2' protein aus wirbeltieren
DE69130675T2 (de) Klonierung und expression eines rhoptry-assoziierten proteins aus p. falciparum

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GENCELL S.A., VITRY-SUR-SEINE, FR

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CENTELION, VITRY SUR SEINE, FR

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC